307 related articles for article (PubMed ID: 16266436)
61. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
[TBL] [Abstract][Full Text] [Related]
62. Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China.
Liu P; You Y; Liao L; Feng Y; Shao Y; Xing H; Lan G; Li J; Ruan Y; Li D
BMC Infect Dis; 2022 May; 22(1):426. PubMed ID: 35509014
[TBL] [Abstract][Full Text] [Related]
63. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
[TBL] [Abstract][Full Text] [Related]
64. Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV.
Trunfio M; Rugge W; Mighetto L; Vai D; Atzori C; Nigra M; Domini S; Borgogno E; Guastamacchia G; Bonora S; Di Perri G; Calcagno A
AIDS; 2020 Nov; 34(13):1899-1906. PubMed ID: 32701580
[TBL] [Abstract][Full Text] [Related]
65. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.
Strain MC; Letendre S; Pillai SK; Russell T; Ignacio CC; Günthard HF; Good B; Smith DM; Wolinsky SM; Furtado M; Marquie-Beck J; Durelle J; Grant I; Richman DD; Marcotte T; McCutchan JA; Ellis RJ; Wong JK
J Virol; 2005 Feb; 79(3):1772-88. PubMed ID: 15650202
[TBL] [Abstract][Full Text] [Related]
66. CSF Inflammation Markers Associated with Asymptomatic Viral Escape in Cerebrospinal Fluid of HIV-Positive Individuals on Antiretroviral Therapy.
Guha D; Misra V; Yin J; Gabuzda D
Viruses; 2023 Aug; 15(9):. PubMed ID: 37766236
[TBL] [Abstract][Full Text] [Related]
67. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
[TBL] [Abstract][Full Text] [Related]
68. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.
García F; Alonso MM; Romeu J; Knobel H; Arrizabalaga J; Ferrer E; Dalmau D; Ruiz I; Vidal F; Frances A; Segura F; Gomez-Sirvent JL; Cruceta A; Clotet B; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
J Acquir Immune Defic Syndr; 2000 Sep; 25(1):26-35. PubMed ID: 11064501
[TBL] [Abstract][Full Text] [Related]
69. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
[TBL] [Abstract][Full Text] [Related]
70. Cerebrospinal fluid viral load, virus isolation, and intrathecal immunoactivation in HIV type 2 infection.
Arvidson N; Gisslén M; Albert J; Brandin E; Svennerholm B; Fuchs D; Hagberg L
AIDS Res Hum Retroviruses; 2004 Jul; 20(7):711-5. PubMed ID: 15307916
[TBL] [Abstract][Full Text] [Related]
71. Neurocognitive impairment in HIV-infected naïve patients with advanced disease: the role of virus and intrathecal immune activation.
Airoldi M; Bandera A; Trabattoni D; Tagliabue B; Arosio B; Soria A; Rainone V; Lapadula G; Annoni G; Clerici M; Gori A
Clin Dev Immunol; 2012; 2012():467154. PubMed ID: 22489249
[TBL] [Abstract][Full Text] [Related]
72. HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy.
Donath M; Wolf T; Stürmer M; Herrmann E; Bickel M; Khaykin P; Göpel S; Gute P; Haberl A; de Leuw P; Schüttfort G; Berger A; Stephan C;
Med Microbiol Immunol; 2016 Dec; 205(6):575-583. PubMed ID: 27469377
[TBL] [Abstract][Full Text] [Related]
73. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102.
Henry K; Katzenstein D; Cherng DW; Valdez H; Powderly W; Vargas MB; Jahed NC; Jacobson JM; Myers LS; Schmitz JL; Winters M; Tebas P;
J Acquir Immune Defic Syndr; 2006 Jun; 42(2):140-8. PubMed ID: 16760795
[TBL] [Abstract][Full Text] [Related]
74. Comparative Analysis of Cell-Associated HIV DNA Levels in Cerebrospinal Fluid and Peripheral Blood by Droplet Digital PCR.
de Oliveira MF; Gianella S; Letendre S; Scheffler K; Kosakovsky Pond SL; Smith DM; Strain M; Ellis RJ
PLoS One; 2015; 10(10):e0139510. PubMed ID: 26431315
[TBL] [Abstract][Full Text] [Related]
75. Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion.
Marcotte TD; Deutsch R; McCutchan JA; Moore DJ; Letendre S; Ellis RJ; Wallace MR; Heaton RK; Grant I;
Arch Neurol; 2003 Oct; 60(10):1406-12. PubMed ID: 14568811
[TBL] [Abstract][Full Text] [Related]
76. Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation.
Wang SX; Ho EL; Grill M; Lee E; Peterson J; Robertson K; Fuchs D; Sinclair E; Price RW; Spudich S
J Acquir Immune Defic Syndr; 2014 Jul; 66(3):303-10. PubMed ID: 24732871
[TBL] [Abstract][Full Text] [Related]
77. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.
Dahl V; Lee E; Peterson J; Spudich SS; Leppla I; Sinclair E; Fuchs D; Palmer S; Price RW
J Infect Dis; 2011 Dec; 204(12):1936-45. PubMed ID: 22021620
[TBL] [Abstract][Full Text] [Related]
78. Ethnicity and discordance in plasma HIV-1 RNA viral load and CD4+ lymphocyte count in a cohort of HIV-1-infected individuals.
Smith PR; Sarner L; Murphy M; James B; Thomas JM; Skinner CJ; Aitken C
J Clin Virol; 2003 Jan; 26(1):101-7. PubMed ID: 12589840
[TBL] [Abstract][Full Text] [Related]
79. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
Hughes MD; Johnson VA; Hirsch MS; Bremer JW; Elbeik T; Erice A; Kuritzkes DR; Scott WA; Spector SA; Basgoz N; Fischl MA; D'Aquila RT
Ann Intern Med; 1997 Jun; 126(12):929-38. PubMed ID: 9182469
[TBL] [Abstract][Full Text] [Related]
80. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients.
Chang L; Ernst T; St Hillaire C; Conant K
Antivir Ther; 2004 Jun; 9(3):431-40. PubMed ID: 15259906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
